Down 87%, is this once-famous stock set to explode like the Rolls-Royce share price?

Unlike the roaring Rolls-Royce share price, this growth stock and former household name has totally bombed. But is it due a big comeback?

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Rolls-Royce (LSE: RR) share price crashed more than 80% when international travel ground to a halt during the pandemic. The FTSE 100 engine maker had to take on enormous debt just to survive.

However, savvy investors who bought in four years ago have made more than 10 times their money by now!

Unfortunately, I only got on board when the stock was already on the way up at 149p. But Rolls-Royce shows the sort of dramatic gains that can be secured when a struggling firm wins back the confidence of investors.

Today, at 547p, Rolls-Royce is trading at around 30 times this year’s forecast earnings. That’s a punchy valuation, especially when the widening Middle East conflict could disrupt the company’s supply chains.

The consensus price target among analysts is only 6% above the current level. So I think it’s safe to assume we won’t be seeing the Rolls-Royce share price rise tenfold again any time soon.

That household name I mentioned

By contrast, Wall Street currently has a $98 target on shares of Moderna (NASDAQ: MRNA). That’s around 70% higher than the present $57.

The firm became a well-known name during the pandemic when its vaccines were among those that came to the rescue. Since then though, vaccine fatigue has set in among the public and sales have dropped off a cliff.

The stock is down 42% this year alone and 87% from a 2021 high of $449.

Inflicting further pain on myself, I’ve just checked my portfolio. This shows my holding in Moderna is now down 60% after I bought shares three times between between mid-2022 and early 2024. Ouch.

What on earth has gone wrong here?

Loss of confidence

Put simply, the market has lost faith in management’s ability to accurately forecast demand for Covid (or any other) vaccine sales. In September, the biotech firm adjusted its 2025 revenue guidance, from $3bn-$3.5bn to $2.5bn-$3.5bn. Basically, it widened the range, but not in the direction investors wanted.

It also now expects to reach operating cash flow breakeven in 2028 instead of 2026. It has nearly $8.5bn in cash, which it reckons will be enough to get it there. But with sluggish sales and ongoing losses, there’s plenty of risk here.

Patience needed

I invested in Moderna because its messenger RNA (mRNA) platform has the potential to be highly scalable and go well beyond Covid.

CEO Stéphane Bancel said: “With mRNA, it’s four letters, like zeros and ones with software. You code everything.” This means the platform has digital characteristics, where more data leads to better results. This is unlike traditional pharmaceutical approaches, where a hit with one drug reveals nothing about the success of another.

According to Moderna, the probability of its drug candidates progressing from phase one to phase three trials is approximately six times higher than the industry average. And despite the near-term challenges, the company still expects to launch 10 products in the next three years across three therapeutic areas.

If the stock ever recovered to reach it’s previous height of $449, then we’d be looking at Rolls-Royce-type returns from $57 today. Of course, that’s a long shot and certainly won’t happen overnight. Moderna needs to start winning back investor confidence first.

But given the potential, I’m going to keep my shares.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Moderna and Rolls-Royce Plc. The Motley Fool UK has recommended Rolls-Royce Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Forget the FTSE 100! Here are 3 dividend shares to consider for a great passive income

If searching for ways to supercharge a passive income portfolio, these non-Footsie dividend shares are worth a closer look, says…

Read more »

Investing Articles

Up 41% and 17%, these FTSE 250 shares still look like bargains to me!

Looking for the best FTSE 250 shares to buy at rock-bottom prices? Here are two Royston Wild thinks deserve close…

Read more »

Illustration of flames over a black background
Investing Articles

Just released: November’s higher-risk, high-reward stock recommendation [PREMIUM PICKS]

Fire ideas will tend to be more adventurous and are designed for investors who can stomach a bit more volatility.

Read more »

Young female analyst working at her desk in the office
Investing Articles

Here’s how I’d target a £23k second income with £300 a month

If I was building a shares portfolio today, here's how I'd go about it. With these strategies I stand a…

Read more »

Investing Articles

Tesla stock, MicroStrategy: here’s what Hargreaves Lansdown investors bought last week

MicroStrategy and Tesla stock were among the most popular investments last week as Donald Trump boosted markets with his election…

Read more »

Investing Articles

1 AI stock worth considering now Stocks and Shares ISAs are safe!

The Budget brought good news for those of us with Stocks and Shares ISAs! I’ve been looking at this one…

Read more »

Engineer Project Manager Talks With Scientist working on Computer
Growth Shares

Up 41% in 1 year, I’m buying more of this growth trust for my Stocks and Shares ISA

A great performance over the last 12 months has pushed our writer to buy more of a very exciting investment…

Read more »

Investing Articles

3 reasons to like the Legal & General dividend

Christopher Ruane explains a trio of reasons why he likes the Legal & General dividend as a source of passive…

Read more »